BARM global trials and evaluations

Cortical Dynamics has supplied BAR Monitors worldwide to 12 hospitals for trials and evaluation including:

St Vincent’s Private Hospital, Sydney
St Vincent’s Private Hospital, Melbourne
Epworth Private Hospitals Richmond & Freemasons,

Melbourne
St Luke’s Hospital, Potts Point, Sydney • Strathfield Private Hospital, Sydney
Cairns Hospital, Cairns
Waikato Hospital, Hamilton, NZ
Hôpital Foch, Paris, France
Southampton General Hospital, UK

BARM has been used in over 200 operations at these hospitals with positive outcomes

BARM advantage

Faster, versatile, sensitive, comprehensive and accurate continuous monitoring

Continuous monitoring of the brain is necessary to diagnose and manage acute deteriorations in brain function and aids optimal management of hypnosis and analgesia. Monitoring minimizes patient distress and agitation essential in facilitating life support equipment and procedures

In ICU patients, overly deep sedation increases the time on mechanical ventilation, leading to increases in mortality, complications and treatment costs

Cortical Dynamics has addressed these issues by developing the electroencephalogram-based (EEG) BAR Monitor. BARM is configured to continually display information related to the clinically relevant state of a patient’s brain condition

In addition to hypnosis, BARM is designed to monitor CI, or pain, which is vital to the management of a sedated mechanically ventilated patient

BARM’s measure of analgesia (CI)

General anaesthetics affect both cortical (superficial brain layers) and sub-cortical (deeper brain regions) structures of the brain. Analgesic effects of anaesthetics reside mostly in sub-cortical structures. Current EEG based depth of anaesthesia monitors provide limited information on sub- cortical mechanisms and thus cannot reliably monitor the effects of analgesics.

Optimal patient care during balanced anaesthesia requires monitoring of both hypnotic and analgesic effects. In ICU patients, monitoring analgesia can avoid adverse outcomes such as prolonged ICU stay and long-term cognitive dysfunction.CI is part of the ongoing research and development of BARM

CI has shown response to opioid concentration, indicating its potential as a measure of analgesic efficacy

Our findings have shown CI responds to varying levels of the analgesic remifentanil, independent of changes in hypnotic level and CCS1

CI has shown sensitivity to detect a low or high dose of fentanyl in patients undergoing cardiac surgery indicating its potential use in titration of fentanyl as an intraoperative anti-nociceptive agent2.Current trials are under way to evaluate CI changes to a range of sedatives in ICU patients

License agreement with Philips

Cortical Dynamics Limited (Cortical) is pleased to announce it has entered into a non-exclusive Licence and Cooperation Agreement with Philips Healthcare North America Corp (Philips) which will enable Cortical to interface it’s Brain Anaesthesia Response Monitor (BARM) into the Philips IntelliVue and Patient Information Center (PIC iX) Monitoring Systems using the IntelliBridge integration product line.